BioSpace News Archive

Lone Star Bio

Researchers take step toward development of universal COVID-19 antibodies

SARS-CoV-2, the virus that causes COVID-19 disease, continues to evolve and evade current vaccine and therapeutic interventions.

May 30, 2024
·
3 min read
Lone Star Bio

Castle Biosciences to Present New Data at 2024 ASCO® Annual Meeting Highlighting Use of DecisionDx®-Melanoma to Identify Early-Stage Melanoma Patients at High Risk of Metastasis to the Central Nervous System

Castle to present a second poster on its DecisionDx®-UM test sharing data from an ongoing prospective, multi-center study of patients with uveal melanoma (UM) led by the Collaborative Ocular Oncology Group (COOG2).

May 30, 2024
·
8 min read
SAB Biotherapeutics Announces Departure of Chief Financial Officer

SAB Biotherapeutics today announced that effective June 4, its Chief Financial Officer Michael King will be departing the company to accept a role as CEO at a privately-held oncology company.

May 30, 2024
·
4 min read
Drug Development

Gilead Provides Update on Phase 3 TROPiCS-04 Study

Gilead Sciences, Inc. (Nasdaq: GILD) today announced topline results from the confirmatory Phase 3 TROPiCS-04 study in locally advanced or metastatic urothelial cancer (mUC).

May 30, 2024
·
16 min read
Biotech Beach

Favorable Oncocyte VitaGraft Kidney Study Results Published in the New England Journal of Medicine

Oncocyte Corporation, a precision diagnostics company, announced that favorable data regarding its lead product VitaGraft™ Kidney was published in the New England Journal of Medicine.

May 30, 2024
·
8 min read
Genetown

Biogen Receives European Commission Approval for QALSODY® (tofersen), the First Therapy to Treat a Rare, Genetic Form of ALS

Biogen Inc announced the European Commission (EC) has granted marketing authorization under exceptional circumstances and maintained orphan designation for QALSODY.

May 30, 2024
·
10 min read
Policy

FDA, USDA, EPA Enhance Efforts to Reduce Food Loss and Waste; Welcome USAID to Interagency Collaborative

The U.S. Food and Drug Administration announced the signing of a formal agreement with the U.S. Department of Agriculture and the U.S. Environmental Protection Agency to renew their Federal Interagency Collaboration to Reduce Food Loss and Waste.

May 30, 2024
·
4 min read
BioCapital

Vanda Pharmaceuticals Announces Completion of Transfer of FDA Marketing Authorization for PONVORY®

Vanda Pharmaceuticals Inc. today announced that ownership of the U.S. New Drug Application and Investigational New Drug Applications for PONVORY ® (ponesimod) has been transferred to Vanda from a Johnson & Johnson Company, which now fully allows Vanda to commercialize PONVORY ® in the U.S.

May 30, 2024
·
5 min read
BioCapital

Vanda Pharmaceuticals Announces Participation in the Jefferies 2024 Global Healthcare Conference

Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the company will participate in the Jefferies 2024 Global Healthcare Conference in New York City on Thursday, June 6, 2024.

May 30, 2024
·
1 min read
Drug Development

Avirmax Biopharma Inc. Receives IND Approval for Phase I/IIa Trial to Treat Wet AMD including PCV

Avirmax Biopharma, Inc. is pleased to announce that it has received Investigational New Drug (IND) approval from the U.S. Food and Drug Administration (FDA) to initiate a Phase I/IIa clinical trial for its gene therapy treatment targeting wet Age-related Macular Degeneration.

May 30, 2024
·
2 min read